FAME II trial demonstrates the importance of targeting treatment to the right patients
A ground breaking international trial, presented yesterday at EuroPCR, has demonstrated for the very first time the true value of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The study highlights the critical importance of targeting these interventions to patients with ischemia and may revolutionise the patient selection procedure for PCI.